149 related articles for article (PubMed ID: 12161049)
1. Impact of different hormone replacement therapy regimens on the size of myoma uteri in postmenopausal period: tibolone versus transdermal hormonal replacement system.
Simsek T; Karakus C; Trak B
Maturitas; 2002 Jul; 42(3):243-6. PubMed ID: 12161049
[TBL] [Abstract][Full Text] [Related]
2. A randomized study of the effects of tibolone and transdermal estrogen replacement therapy in postmenopausal women with uterine myomas.
Fedele L; Bianchi S; Raffaelli R; Zanconato G
Eur J Obstet Gynecol Reprod Biol; 2000 Jan; 88(1):91-4. PubMed ID: 10659924
[TBL] [Abstract][Full Text] [Related]
3. Comparison of transvaginal ultrasonography and endometrial biopsy in endometrial surveillance in postmenopausal HRT users.
Hänggi W; Bersinger N; Altermatt HJ; Birkhäuser MH
Maturitas; 1997 Jun; 27(2):133-43. PubMed ID: 9255748
[TBL] [Abstract][Full Text] [Related]
4. The effects of add-back therapy with tibolone on myoma uteri.
Göçmen A; Kara IH; Karaca M
Clin Exp Obstet Gynecol; 2002; 29(3):222-4. PubMed ID: 12519049
[TBL] [Abstract][Full Text] [Related]
5. [The effects of menopausal replacement therapy in women with uterine myomas].
Orsini G; Pinto V; Di Biase S; D'Altorio C; Lanzilotti G
Minerva Ginecol; 1999 Nov; 51(11):421-5. PubMed ID: 10726441
[TBL] [Abstract][Full Text] [Related]
6. Uterine myoma in postmenopause: a comparison between two therapeutic schedules of HRT.
Polatti F; Viazzo F; Colleoni R; Nappi RE
Maturitas; 2000 Nov; 37(1):27-32. PubMed ID: 11099870
[TBL] [Abstract][Full Text] [Related]
7. The short-term effects of different regimens of hormone replacement therapy on left ventricular structure and performance in healthy postmenopausal women. A prospective, controlled echocardiographic study.
Fenkci V; Yilmazer M; Alpaslan M; Onrat E; Fenkci S
Gynecol Obstet Invest; 2003; 55(3):139-44. PubMed ID: 12865592
[TBL] [Abstract][Full Text] [Related]
8. Differential effects on the androgen status of postmenopausal women treated with tibolone and continuous combined estradiol and norethindrone acetate replacement therapy.
Dören M; Rübig A; Coelingh Bennink HJ; Holzgreve W
Fertil Steril; 2001 Mar; 75(3):554-9. PubMed ID: 11239541
[TBL] [Abstract][Full Text] [Related]
9. Impact on uterine bleeding and endometrial thickness: tibolone compared with continuous combined estradiol and norethisterone acetate replacement therapy.
Dören M; Rübig A; Coelingh Bennink HJ; Holzgreve W
Menopause; 1999; 6(4):299-306. PubMed ID: 10614676
[TBL] [Abstract][Full Text] [Related]
10. Long term effects of Tibolone on postmenopausal women with uterine myomas.
Gregoriou O; Konidaris S; Botsis D; Papadias C; Makrakis E; Creatsas G
Maturitas; 2001 Oct; 40(1):95-9. PubMed ID: 11684378
[TBL] [Abstract][Full Text] [Related]
11. Continuous versus cyclical transdermal estrogen replacement therapy in postmenopausal women: influence on climacteric symptoms, body weight and bleeding pattern.
Lübbert H; Nauert C
Maturitas; 1997 Dec; 28(2):117-25. PubMed ID: 9522319
[TBL] [Abstract][Full Text] [Related]
12. Transdermal hormone replacement therapy in postmenopausal women with uterine leiomyomas.
Palomba S; Sena T; Noia R; Di Carlo C; Zullo F; Mastrantonio P
Obstet Gynecol; 2001 Dec; 98(6):1053-8. PubMed ID: 11755553
[TBL] [Abstract][Full Text] [Related]
13. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels.
Pluchino N; Genazzani AD; Bernardi F; Casarosa E; Pieri M; Palumbo M; Picciarelli G; Gabbanini M; Luisi M; Genazzani AR
Gynecol Endocrinol; 2005 Mar; 20(3):144-9. PubMed ID: 16019353
[TBL] [Abstract][Full Text] [Related]
14. Hormone replacement therapy lowers plasma Lp(a) concentrations. Comparison of cyclic transdermal and continuous estrogen-progestin regimens.
Taskinen MR; Puolakka J; Pyörälä T; Luotola H; Bjäörn M; Kääriänen J; Lahdenperä S; Ehnholm C
Arterioscler Thromb Vasc Biol; 1996 Oct; 16(10):1215-21. PubMed ID: 8857916
[TBL] [Abstract][Full Text] [Related]
15. Effect of tibolone on postmenopausal women with myomas.
Gregoriou O; Vitoratos N; Papadias C; Konidaris S; Costomenos D; Chryssikopoulos A
Maturitas; 1997 Jun; 27(2):187-91. PubMed ID: 9255754
[TBL] [Abstract][Full Text] [Related]
16. Effects of hormone replacement therapy on postmenopausal uterine myoma.
Colacurci N; De Franciscis P; Cobellis L; Nazzaro G; De Placido G
Maturitas; 2000 May; 35(2):167-73. PubMed ID: 10924843
[TBL] [Abstract][Full Text] [Related]
17. Resistance of pelvic arteries and plasma lipids in postmenopausal women: comparative study of tibolone and continuous combined estradiol and norethindrone acetate replacement therapy.
Dören M; Rübig A; Coelingh Bennink HJ; Holzgreve W
Am J Obstet Gynecol; 2000 Sep; 183(3):575-82. PubMed ID: 10992176
[TBL] [Abstract][Full Text] [Related]
18. Endometrial safety, overall safety and tolerability of transdermal continuous combined hormone replacement therapy over 96 weeks: a randomized open-label study.
Samsioe G; Boschitsch E; Concin H; De Geyter C; Ehrenborg A; Heikkinen J; Hobson R; Arguinzoniz M; Ibarra de Palacios P; Scheurer C; Schmidt G;
Climacteric; 2006 Oct; 9(5):368-79. PubMed ID: 17080587
[TBL] [Abstract][Full Text] [Related]
19. The long-term effects of oral and transdermal postmenopausal hormone replacement therapy on nitric oxide, endothelin-1, prostacyclin, and thromboxane.
Ylikorkala O; Cacciatore B; Paakkari I; Tikkanen MJ; Viinikka L; Toivonen J
Fertil Steril; 1998 May; 69(5):883-8. PubMed ID: 9591497
[TBL] [Abstract][Full Text] [Related]
20. [Relation between hormonal therapy and tibolone with SERMs in postmenopausal women's myomes growth].
Carranza Lira S
Ginecol Obstet Mex; 2008 Oct; 76(10):610-4. PubMed ID: 19062511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
